Cargando…
Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19
Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250997/ https://www.ncbi.nlm.nih.gov/pubmed/35795188 http://dx.doi.org/10.3389/fcimb.2022.916012 |